Guardant Health (GH) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.42
- Estimate
- -$0.39
- Surprise
- -7.8%
- Revenue (period 2026-06-30)
- $335.0M
- Score at report (before → after)
- 5.3 → 5.6/10
Revenue source: xbrl.
How the report landed
Guardant Health (GH) reported a wider loss than forecast — diluted EPS of -$0.42 against the -$0.39 estimate (a 7.8% shortfall). TrendMatrix's engine moved from Data Issue (5.3/10) to Hold at 5.6/10 after the report — the engine's score rose despite the miss.
Where TrendMatrix's rating stands now
TrendMatrix currently rates GH Sell at 5.5/10.
2 of the last 4 quarters beat the estimate; this quarter's -7.8% surprise compares with a +2.7% four-quarter average. Next scheduled report: 2026-10-28.
What supports the rating
- Strong growth profile
- Positive momentum
What argues against it
- Concentration risk — Product: tests (94.0%)
- Analyst target reached - limited upside remaining
- Near 52-week high (3.3% away)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $170.65
- Price target
- $174.86
- Stop
- $158.74
- Upside to target
- +2.5%
- Reward-to-risk
- 0.2:1
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
GH at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $22.91B
- P/E (fwd)
- -379.2
- 52-week range
- $53.40–$176.58
- Off 52-week high
- 3.4%
- RSI (14)
- 62
- Volume vs avg
- 0.84×
- Score today
- 5.5/10